Cyclapolin 9

Cat. No.:	HY-15159
CAS No.:	40533-25-3
Molecular Formula:	$C_9H_4F_3N_3O_4S$
Molecular Weight:	307.21
Target:	Polo-like Kinase (PLK)
Pathway:	Cell Cycle/DNA Damage
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 20 mg/mL (65.10 mM; ultrasonic and warming and heat to 80°C)

Preparing Stock Solutions	Solvent / Mass / Concentration	1 mg	5 mg	10 mg
	1 mM	3.2551 mL	16.2755 mL	32.5510 mL
	5 mM	0.6510 mL	3.2551 mL	6.5102 mL
	10 mM	0.3255 mL	1.6276 mL	3.2551 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Cyclapolin 9 is a potent, selective and ATP-competitive polo-like kinase 1 (PLK1) inhibitor with an IC_{50} of 500 nM. Cyclapolin 9 is inactive against other kinases[1][2].

IC_{50} & Target

PLK1
500 nM (IC_{50})

In Vitro

Cyclapolin 9 (3 μM) reduces electric field stimulation (EFS)-induced contractions of prostate strips. The α1-adrenergic smooth muscle contraction in the human prostate can be inhibited by Cyclapolin 9[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Martin Hennenberg, et al. Inhibition of Prostate Smooth Muscle Contraction by Inhibitors of Polo-Like Kinases. Front Physiol. 2018 Jun 15;9:734.

[2]. Campbell McInnes, et al. Inhibitors of Polo-like kinase reveal roles in spindle-pole maintenance. Nat Chem Biol. 2006 Nov;2(11):608-17.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA